Review

Pro/con clinical debate: Steroids are a key component in the treatment of SARS
Charles D Gomersall¹, Marcus J Kargel² and Stephen E Lapinsky³

¹Associate Professor, Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
²Critical Care Fellow, Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada
³Site Director, Intensive Care Unit, Mount Sinai Hospital and Associate Professor of Medicine, Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada

Correspondence: Critical Care Editorial Office, editorial@ccforum.com

Published online: 26 January 2004
This article is online at http://ccforum.com/content/8/2/105
© 2004 BioMed Central Ltd (Print ISSN 1364-8535; Online ISSN 1466-609X)

Abstract

SARS (severe acute respiratory syndrome) proved an enormous physical and emotional challenge to frontline health care workers throughout the world in late 2002 through to mid 2003. A large percentage of patients (many being health care workers themselves) became critically ill. Unfortunately, clinicians caring for these individuals did not have the advantage of previous experience or research data on which to base treatment decisions. As a result, at least early in the outbreak, a ‘best guess approach’ and/or anecdotes drove therapy. In many centres systemic steroids, which carry many potential downsides, became a mainstay of therapy. In this issue of Critical Care, two groups that have frontline experience of SARS debate the role of steroids. Let us hope and pray together that we never have the patient population needed to resolve the questions the two sides raise.

Keywords critical care, respiratory failure, SARS, steroids, viral pneumonia

The scenario

Unfortunately, in the winter of 2004 SARS (severe acute respiratory syndrome) emerges in the world once again, and health care workers in your institution begin to develop the illness. Patients with SARS start to develop critical illness and you are asked to become involved in their care. You have read that during the first outbreak of SARS steroids were a commonly employed therapy. Despite this you worry about the adverse effects of steroid therapy, especially in critically ill patients.

Pro: Yes, steroids are a key component of the treatment regimen for SARS
Charles D Gomersall

SARS is a potentially life-threatening disease caused by infection with SARS coronavirus. The early phase of the disease appears to be due to the virus itself whereas the later phase is thought to be due to an inflammatory response. Quantitative reverse transcriptase polymerase chain reaction of nasopharyngeal aspirates has shown that the viral load peaks at about 10 days from symptom onset [1], and serum concentrations of IL-6, IL-8, IL-16 and tumour necrosis factor-α are most markedly raised 8–14 days from disease onset [2]. In addition, the histological changes in the lungs of patients who died from SARS suggest cytokine dysregulation [3]. Thus, the available data suggest that the clinical manifestations of SARS in the second week of illness are predominantly due to an excessive immune response to viral infection rather than to infection itself. Because admission to the intensive care unit (ICU) occurs 8–9 days after symptom onset and the median duration of ICU stay is 8.5–14.5 days [4–6], it is likely that most critically ill patients are in this immunological phase. Therefore, a logical approach is to modify the immune response with anti-inflammatory agents such as corticosteroids.
The majority of critically ill patients with SARS develop acute respiratory distress syndrome (ARDS); not only do the vast majority meet the criteria for ARDS [4–6] but also computed tomography of the lungs 22–54 days after the onset of ARDS shows changes consistent with late phase ARDS [7]. Data from other patients with ARDS suggest that high-dose corticosteroids may have a beneficial effect in those who fail to improve by day 7 of respiratory failure [8]. Other ARDS data indicate that steroids do not worsen outcome despite the inclusion of patients with ARDS due to sepsis, and that the incidence of infectious complications is unaffected by the administration of very high doses of corticosteroid [9].

Finally, in other viral pneumonias corticosteroids may be of benefit. In a rat model of respiratory syncytial virus pneumonitis the histological changes of pneumonitis were significantly less marked in animals treated with an antiviral and corticosteroids than in control animals treated with an antiviral alone [10]. Human data on the effect of corticosteroids in viral pneumonia are limited, but in a retrospective study of patients with severe varicella pneumonia the patients treated with steroids had a shorter hospital and ICU stay despite having a lower arterial oxygen tension/fractional inspired oxygen ratio on admission to the ICU [11].

In the absence of randomized clinical trials, intensivists have the choice of providing only supportive treatment (almost none of which is based on randomized controlled trials) or treating patients on the basis of the pathophysiology of SARS. The severe respiratory failure, which occurs in the later phase of SARS and results in critical illness, appears to be due to an excessive inflammatory response to infection with SARS coronavirus. This suggests that corticosteroids have a role to play in the treatment of critically ill patients with SARS, namely to ameliorate the inflammatory response and possibly decrease the progression to fibrosis in those who develop ARDS.

Con: No, steroids are not a key component of the treatment regimen for SARS

Marcus J Kargel and Stephen E Lapinsky

Systemic steroids have been used in the treatment of SARS based on the hypothesis that disease manifestations are in part due to the host's inflammatory response. Many questions regarding the use of steroids in the treatment of SARS remain unanswered, including the efficacy of this treatment, the appropriate timing of initiation of treatment, and the dose and duration of therapy.

Steroid therapy causes significant adverse effects, and this remains true in patients with SARS. Wang and coworkers [12] described a case of fatal aspergillosis, and recent press reports indicate that a large number of SARS survivors in Hong Kong are now suffering from steroid-induced avascular necrosis [13,14]. Myopathy and polyneuropathy occur in ARDS patients treated with steroids [15], and this has been noted in follow up of SARS patients (S Herridge, personal communication, 2003).

Currently, there is no published evidence demonstrating an improvement in morbidity or mortality with steroid treatment in SARS. None of the case series that evaluated predictors of outcome have demonstrated an association between the lack of steroid use and poor clinical outcome [4,16,17]. Lew and coworkers [5] found no significant difference in outcome between 15 patients treated with immunoglobulin and methylprednisolone and 30 patients who were not administered those agents. A report from China [18] suggests that a regimen including high-dose steroids was associated with reduced mortality, but that study exhibits a potentially biased randomization scheme, nonblinded assessments, and significant cross-over between treatment groups.

SARS clinicians prescribed steroids under desperate circumstances based on anecdotal experience and on a rudimentary understanding of the role of host inflammatory damage in this condition. We would not recommend the routine use of steroids in all SARS patients with respiratory failure. Large randomized clinical trials are needed to help resolve the many unanswered questions regarding the role, dose and timing of corticosteroids for SARS.
Pro response: How great is the risk of adverse effects?

Charles Gomersall

First, none of the studies that evaluated predictors of outcome were adequately powered to exclude a clinically important effect of steroids [4,5,16]. Second, what is at issue is the incidence of steroid-related complications in SARS patients, not whether steroids have adverse effects. The incidence has not been reliably determined. It is inconsistent to ask for evidence of benefit from randomized controlled trials yet accept evidence of harm from the popular press. Third, agreement between results of meta-analyses and large randomized controlled trials is poor [23].

Con response: Research first

Marcus J Kargel and Stephan E Lapinsky

The existing anecdotal and retrospective literature does not conclusively support the use of corticosteroids for treatment of SARS. Although steroids are often used in desperate and life-threatening situations, no benefit has been proven for this disease or related conditions such as ARDS or other viral pneumonias. History has shown that therapy based on anecdotes, even with sound pathophysiological support, may not prove to be beneficial in formal studies [24]. Given the potential severe side effects of steroid therapy, it is essential that randomized controlled trials be performed. Research protocols should be pre-developed to be initiated promptly, should SARS return.

References

1. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KL, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY, HKU/UCH SARS study group: Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003, 361:1767-1772.
2. Beijing Group of National Research Project for SARS: Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chinese Med J 2003, 116:1283-1287.
3. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Chan KH, Tsang NC, Guan Y, Yuen KY, Peiris JS: Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003, 361:1773-1778.
4. Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, Slutsky AS, Stewart TE, for the Toronto SARS Critical Care Group: Critically ill patients with severe acute respiratory syndrome. JAMA 2003, 290:367-373.
5. Lew TWK, Kwek TK, Tai D, Ernest A, Loo S, Singh K, Wain KMW, Chan Y, Yim CF, Bek SL, Kor AC, Yap WS, Chelliah YR, Lai YC, Geh SK: Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003, 290:374-380.
6. Gomersall CD, Joynt GM, Lam P, Li T, Yap F, Lam D, Buckley TA, Sung JY, Hui DS, Antonio GE, Ahuja AT, Leung P: Short term of outcome of critically ill patients with severe acute respiratory syndrome. Intensive Care Med 2004, in press.
7. Joynt GM, Antonio GE, Lam P, Wong KT, Li T, Gomersall CD, Ahuja AT: Thin-section computed tomography abnormalities in patients with late adult respiratory distress syndrome (ARDS) caused by severe acute respiratory syndrome (SARS). Radiology 2004, in press.
8. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, Tolley EA: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998, 280:159-165.
9. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, Kariman K, Higgins S, Bradley R, Metz CA: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987, 317:1565-1570.
10. Ottolini MG, Curtis SJ, Porter DD, Mathews A, Richardson JY, Hemming VG, Prince GA: Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob Agents Chemother 2002, 46:2299-2302.
11. Mer M, Richards GA: Corticosteroids in life-threatening varicella pneumonia. Chest 1998, 114:426-431.
12. Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W: Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003, 349:507-508.
13. Reuters: SARS drugs tied to bone disease: steroid treatment may have caused serious side-effects. 3 October 2003 [http://www.msnbc.com/news/978570.asp?so=1&cp=1]
14. Terra Wire: Some recovered SARS patients in Hong Kong have bone disease: official. 9 November 2003 [http://www.terra-daily.com/2003/031109090254.dlc4wtoq.html]
15. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, Stewart TE, Barr A, Cook D, Slutsky AS; Canadian Critical Care Trials Group: One year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003, 348:683-693.
16. Booth CM, Matukas LM, Tominson GA, Rachlis AR, Rose DB, Dwoish HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephtimos IE, Kitai I, Mederski BD, Shadowitz SB, Gold WL, Hawryluck LA, Rea E, Chenkin JS, Cescon DW, Poutanen SM, Detsky AS: Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003, 289:2801-2809.
17. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF, Liu SF, Szeto CC, Chung S, Sung JJ: A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003, 348:1896-1994.
18. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, Hawkey PM: Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003, 52:715-720.
19. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr: Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23:1430-1439.
20. Lefering R, Neugebauer E: Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995, 23:1294-1303.
21. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, Wong PC, Li PC, Ho PL, Lam WK, Ng CK, Ip MS, Lai KN, Chan-Yeung M, Tsang KW: High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003, 168:1449-1456.
22. So LK, Lau AC, Yam LY, Cheung TM, Poon E, Yung RW, Yuen KY: Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003, 361:1615-1617.
23. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997, 337:536-542.
24. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, and the CAST investigators: Mortality and morbidity in patients receiving encaïne, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781-788.